The Zebrafish (Danio rerio) Embryo as a Model for Developmental and Cardiovascular Toxicity: Principles, Mechanisms and Applications
A. Abarnadevika
*
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
D. K. Shanmuganathan
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
Arvind G. Krishna
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
D. Christel Joy
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
S. Gokulnath
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
R. Sanjeev Raj
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
P. Vaishnav
Department of Pharmacology, KMCH College of Pharmacy (Approved by PCI & Affiliated to the Tamil Nadu Dr. M. G. R. Medical University), India.
*Author to whom correspondence should be addressed.
Abstract
Background: Embryonic zebrafish (Danio rerio) has emerged as a leading vertebrate model in developmental biology and cardiovascular toxicology. It effectively bridges the gap between high-throughput in vitro assays and mammalian in vivo systems, enabling efficient evaluation of drugs and chemical-induced cardiotoxicity and developments.
Key Advantages: The model offer approximately 70 percent genetic similarity to humans, conserved cardiovascular physiology (including a distinct QT interval), rapid external embryonic development, optical transparency for live imaging, small size, and high fecundity. A unique strength is that embryos with severe cardiac defects survive via passive oxygen diffusion, permitting detailed phenotypic analysis of otherwise lethal cardiac malformations unlike in mammalian models.
Screening Applications and Phenotypic Endpoints: Zebrafish embryos enable cost-effective, large-scale screening of drugs and environmental toxins (greatly surpassing rodent throughput). They facilitate detection of structural cardiotoxicity (e.g. Pericardial edema, heart looping defects) and functional cardiotoxicity (e.g. Bradycardia, reduced cardiac output), including effects without overt morphological alterations.
Chemical Sensitivity and Mechanistic Features: The model is highly sensitive to diverse chemical classes, including tyrosine kinase inhibitors, immunosuppressants (e.g. Cyclosporine A), antibiotics (e.g. Ciprofloxacin), and fungicides (e.g. Iprodione, thiram). Environmental factors such as pH modulate toxicity and uptake of ionizable compounds. Conserved pathways include oxidative stress and p53-mediated apoptosis, with compound-specific molecular signatures (e.g. Cyclosporine A inhibits Wnt signalling; ciprofloxacin disrupts calcium signalling).
Experimental capabilities: The zebrafish embryo supports pathway-specific rescue experiments (e.g., Wnt activators, antioxidants) and high-throughput screening of cardioprotective agents.
Conclusion and Impact: Overall, the embryonic zebrafish model plays a pivotal role in elucidating early cardiac developmental defects, reducing attrition risks during drug discovery, and establishing safety thresholds for environmental chemicals.
Keywords: Zebrafish, cardiotoxicity, developmental toxicity, high-throughput screening, oxidative stress, molecular mechanisms